Garrison

Focused on identifying undervalued, core opportunities in the market. A seasoned financial analyst with 16 years of experience, specializing in macroeconomics.

[Garrison @A1Tay____]

🔥 $OKLO — AI's next bottleneck isn't computing.

It's power.

⚛️ Advanced nuclear
🏭 Data center energy demand
🤝 Sam Altman-backed vision

The AI race is creating an electricity race.

The question:

Who can deliver reliable power at scale?

OKLO is betting on nuclear being part of the answer.

Big vision.

Now Wall Street wants execution.

#OKLO #AIInfrastructure #Energy

[Garrison @A1Tay____]

🚨 $ABVX — The science is becoming harder to ignore.
Now the market has to decide what it's worth.
Here's what stands out:
🧬 Phase 3 ABTECT met its primary endpoint, with both obefazimod doses delivering statistically significant remission over placebo.
📊 Clinical remission exceeded 50% in the maintenance study, versus about 10% for placebo.
💰 Abivax also secured $920M in financing, giving it the capital to push toward regulatory filings and commercial launch.
Here's my view:
Most biotech rallies end with good data.
The biggest ones begin when investors believe the company can execute after the data.
ABVX has crossed the first hurdle.
Now Wall Street is watching the second.
Commercialization.
That's where the next re-rating could come from.
#ABVX #Biotech #Healthcare #Stocks

[Garrison @A1Tay____]

🚨 $BBAI — The AI trade is evolving.
It's no longer about hype.
It's about contracts.
Here's what caught my attention:
📈 Backlog remains above $1B, giving revenue visibility few small-cap AI names can match.
🏛 Government and defense customers continue to drive demand as AI adoption shifts from pilots to real-world deployment.
🤖 https://t.co/LMhCDVWrat isn't competing with ChatGPT.
It's building mission-critical AI for defense, intelligence and national security.
My takeaway:
The market has rewarded AI stories.
The next winners will be the companies that convert backlog into cash flow.
If execution keeps improving...
BBAI could earn a higher multiple than many investors expect.
In AI, contracts matter more than headlines.
#BBAI #AI #DefenseTech #Stocks

[Garrison @A1Tay____]

🚨 $SLS — Biotech doesn't reward promises.
It rewards catalysts.
Here's why SLS is back on my radar:
🧬 The REGAL Phase 3 study for GPS (galinpepimut-S) remains the company's defining value driver in AML.
💉 SLS also continues advancing SLS009, targeting difficult-to-treat acute myeloid leukemia, expanding its pipeline beyond a single asset.
💰 With recent financing, the company has extended its cash runway to support upcoming clinical milestones.
My view:
The downside is tied to clinical risk.
The upside is tied to data.
If REGAL delivers positive survival results, today's valuation could look disconnected from the commercial opportunity.
In biotech, timing matters.
For SLS, the clock is ticking toward the next major catalyst.
#SLS #Biotech #AML #Stocks

[Garrison @A1Tay____]

$SPCX says it will build Terafab in Texas, with an initial investment of $16.8B.

[Garrison @A1Tay____]

$NVDA gets another vote of confidence from Cathie Wood.

ARK Invest reportedly bought roughly $17.6M of $NVDA shares today.
#NVDA #NVIDIA #ARKInvest #AI

[Garrison @A1Tay____]

$VTRS has completed the sale of global rights to its dry-eye treatment Tyrvaya.

The company also raised the midpoint of several 2026 full-year financial guidance metrics during its earnings call.

By monetizing a mature asset and optimizing its portfolio, $VTRS is sharpening its focus on core businesses and capital allocation.

#VTRS #Viatris #Biotech #Pharma

[Garrison @A1Tay____]

$NVDA is back in focus.

According to posts circulating on X, Elon Musk said SpaceX and Tesla are heavily favoring $NVDA for AI chip purchases.

Meanwhile, 2026 capex from the major cloud giants continues to rise as AI data center buildouts accelerate.

As long as AI infrastructure spending keeps growing, the AI hardware boom is far from over.

#NVDA #NVIDIA #AI #SpaceX #Tesla

[Garrison @A1Tay____]

$MRNA Gains 4% on Key Flu Vaccine Approval

$MRNA shares gained about 4% after the company announced FDA approval for its mRNA flu vaccine.

The approval marks an important step in diversifying $MRNA’s business as demand for COVID-19 vaccines declines.

The new product expands Moderna’s vaccine portfolio and could provide a new growth driver.

#MRNA #Moderna #mRNA #Vaccines #Biotech

[Garrison @A1Tay____]

$LLY delivered a strong Q2 performance.

Strong sales of Zepbound and Mounjaro helped the company raise its 2026 full-year guidance.

Shares jumped 4.86% following the earnings report.

The results also eased concerns that demand for GLP-1 weight-loss drugs may be cooling.

#LLY #EliLilly #Zepbound #Mounjaro #GLP1

[Garrison @A1Tay____]

$PINS has hired David Blincoe as its new global head of content.

The appointment strengthens $PINS’ focus on content, creators and platform engagement while supporting its broader monetization strategy.

#PINS #Pinterest #SocialMedia #Content

[Garrison @A1Tay____]

$AMZN Pharmacy is expanding access to weight-loss medications.

Through a new Medicare transition program, eligible patients can access certain weight-loss drugs for as little as $50 per month.

The move further expands $AMZN’s presence in online pharmacy and healthcare while potentially driving growth in its weight-loss drug business.

#AMZN #AmazonPharmacy #Healthcare #WeightLoss

[Garrison @A1Tay____]

$KEEL Q2 Earnings: 3 Key AI Conversion Metrics

$KEEL reports Q2 earnings on August 10, with its AI data center pivot entering a critical phase.

Three things to watch:

CapEx & financing: Converting 575MW into AI-ready data centers could require $8M–$10M per MW. Will additional debt or equity financing be needed?
Hyperscaler deals: Can $KEEL secure long-term agreements with major cloud players such as $MSFT, $AMZN, $GOOGL or $ORCL?
Supply chain: Large transformers and chillers can face 2–3 year lead times. Has Keel secured critical equipment in advance?

Power availability is only the first step. Infrastructure execution and hyperscaler contracts will determine whether $KEEL’s AI pivot can translate into real value.

#KEEL #AI #DataCenters #HPC

[Garrison @A1Tay____]

$SOBR reports Q2 earnings before the market opens on August 6.

Analysts expect roughly $530K in Q2 revenue, while restructuring and business wind-down costs are likely to keep EPS under pressure.

With the legacy business terminated at the end of July, investors will be watching management’s update on the CWV merger timeline and the future direction of its green energy business.

#SOBR #SmallCap #Energy

[Garrison @A1Tay____]

$SLS REGAL Trial Enters Quiet Period, Readout Nears

As of mid-May, the trial had recorded 78 of 80 required events, leaving just 2 events before the final trigger.

The company has now entered a clinical update quiet period. Once the 80th event occurs, the database will be locked and topline data will follow.

$SLS is also preparing for a potential BLA submission.

#SLS #Biotech #AML #Cancer

[Garrison @A1Tay____]

$TSLA July Sales Diverge: China Gains, Europe Splits

$TSLA July deliveries are showing a clear regional split.

China continues to strengthen, with sales rising for the 9th consecutive month.

Europe remains highly uneven:
France +86%
Denmark +52%
Norway -97%
Spain -81%
Italy -77%
China momentum remains strong, while European deliveries continue to vary sharply by market.
#TSLA #Tesla #EV #ElectricVehicles

[Garrison @A1Tay____]

$IBRX Q2 Revenue Hits Record, Losses Widen

Revenue reached $51.24M, beating the $49.7M estimate. Core product revenue surged 92% YoY to $50.7M, driven by strong ANKTIVA demand.

But losses widened sharply: net loss reached $230M, with EPS at -$0.22 versus the expected -$0.08.

H1 2026 revenue totaled $94.8M, up 121% YoY.

Shares opened roughly 5.2% lower at $6.78 following the earnings release.

#IBRX #ANKTIVA #Biotech #Cancer

[Garrison @A1Tay____]

$SPCX Q2 revenue jumped 92% YoY to $7.81B, while net loss narrowed to $541M.

AI spending is accelerating even faster: quarterly CapEx hit $18.37B, with $15.83B going toward AI infrastructure.

Starlink surpassed 12M users, while AI revenue surged 247% YoY.

Elon Musk is targeting $1T in annual revenue by 2030, alongside plans for space data centers, Starship and next-gen Starlink satellites.

Near-term focus: August 6 lockup expiration, with roughly 911M shares potentially entering the market.

#SPCX #SpaceX #Starlink #AI #DataCenters

[Garrison @A1Tay____]

Moderna initiates first human trial of its Bondi-Bugeo Ebola vaccine. $MRNA

[Garrison @A1Tay____]

Trump’s tariff refund program involves billions of dollars in refunds for major corporations.

$WMT: $2.4B
$AAPL: $2.2B
$TGT: $2.2B
$F: $1.3B
$NKE: $1.0B
$AMZN: $600M
$GM: $500M
$UPS: $500M

#WMT #AAPL #TGT #AMZN #Tariffs